Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $476.95, moving +1.45% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78% ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Co. (WFC), Abbott ...

This was the stock's second consecutive day of gains.

Following an unprecedented AI chip demand, NVIDIA recently became the first company to reach a market capitalization of $4 ...

The stock's rise snapped a three-day losing streak.

Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Morgan Stanley's analyst, Terence Flynn, sticks to his guns with a Hold rating for Vertex Pharmaceuticals, pegging the price ...

NRI PULSE STAFF REPORT The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are ...